Newsbenzinga
Keros Therapeutics Sees Initial Phase 2 Rinvatercept DMD Data In 1H27; Cash $259.5M Funds Operations Into 2H28
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…